Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results.
Fiche publication
Date publication
février 2022
Journal
Gastroenterology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Panés J, Colombel JF, D'Haens GR, Schreiber S, Panaccione R, Peyrin-Biroulet L, Loftus EV, Danese S, Tanida S, Okuyama Y, Louis E, Armuzzi A, Ferrante M, Vogelsang H, Hibi T, Watanabe M, Lefebvre J, Finney-Hayward T, Gonzalez YS, Doan TT, Mostafa NM, Ikeda K, Xie W, Huang B, Petersson J, Kalabic J, Robinson AM, Sandborn WJ
Lien Pubmed
Résumé
SERENE UC evaluated the efficacy of higher adalimumab induction and maintenance dose regimens in patients with ulcerative colitis (UC).
Mots clés
Adalimumab, clinical trial result, inflammatory bowel disease, moderately to severely active ulcerative colitis, monoclonal antibody
Référence
Gastroenterology. 2022 Feb 25;: